Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on December 1, 2025 to a newly hired employee under its 2023 Inducement Plan.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on December 1, 2025 to a newly hired employee under its 2023 Inducement Plan.
The awards permit purchase of up to 15,500 shares of common stock. Options vest over a four-year schedule: 25% of the shares vest on the one-year anniversary of the vesting commencement date, then 1/48th of the shares vest monthly for the remaining 36 months, subject to continued service.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SNDX
In the Dec 4 session, SNDX gained 0.15%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement options
- 15,500 shares
- Stock options granted to one new employee on December 1, 2025
- Vesting period
- 4 years
- Total vesting duration for the inducement stock options
- Cliff vesting portion
- 25%
- Portion vesting on the one-year anniversary of vesting commencement
- Monthly vesting fraction
- 1/48th
- Monthly vesting of remaining options over the following 36 months
- Monthly vesting duration
- 36 months
- Period over which remaining options vest monthly
Historical Context
-
Detailed Revuforj data from 12 ASH 2025 abstracts in acute leukemias.
-
Inducement stock options for a new hire under 2023 Inducement Plan.
-
CEO fireside chat announced for Evercore Healthcare Conference webcast.
-
Inducement options for four new employees under 2023 Inducement Plan.
-
Q3 2025 revenue, Revuforj launch metrics, and business update reported.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement awards financial
stock options financial
vesting technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.